Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06017271 |
Recruitment Status :
Not yet recruiting
First Posted : August 30, 2023
Last Update Posted : August 30, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Pulmonary Embolism Lung Cancer | Diagnostic Test: CTPA (computed tomography pulmonary angiography) |
Study Type : | Observational |
Estimated Enrollment : | 160 participants |
Observational Model: | Cohort |
Time Perspective: | Retrospective |
Official Title: | Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer |
Estimated Study Start Date : | September 30, 2023 |
Estimated Primary Completion Date : | October 30, 2023 |
Estimated Study Completion Date : | June 30, 2024 |
Group/Cohort | Intervention/treatment |
---|---|
PE group
The CTPA diagnosis suggest pulmonary embolism
|
Diagnostic Test: CTPA (computed tomography pulmonary angiography)
The CTPA diagnosis suggest or did not suggest pulmonary embolism. |
control group
The CTPA diagnosis did not suggest pulmonary embolism
|
Diagnostic Test: CTPA (computed tomography pulmonary angiography)
The CTPA diagnosis suggest or did not suggest pulmonary embolism. |
- EAT volume [ Time Frame: May, 20, 2023 ]volume of epicardial adipose tissue (EAT), Cm3
- EAT density [ Time Frame: May, 20, 2023 ]density of epicardial adipose tissue (EAT) , Hounsfield Units (HU)
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- The pathological diagnosis was lung cancer
- Pulmonary artery was evaluated by CTA during hospitalization.
Exclusion Criteria:
- Patients with incomplete clinical data
- Patients with no follow-up data
- Patients with a history of PE before diagnosis of lung cancer
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06017271
Contact: Yang Yan | 13259882601 | yangyan3@xjtu.edu.cn | |
Contact: Haichen Wang | 18991232986 | whccvsdc@xjtufh.edu.cn |
China, Shaanxi | |
First Affiliated Hospital of Xian Jiaotong University | |
Xi'an, Shaanxi, China, 710061 |
Study Director: | Yang Yan | First Affiliated Hospital Xi'an Jiaotong University | |
Principal Investigator: | Haichen Wang | First Affiliated Hospital Xi'an Jiaotong University |
Responsible Party: | First Affiliated Hospital Xi'an Jiaotong University |
ClinicalTrials.gov Identifier: | NCT06017271 |
Other Study ID Numbers: |
XJTU1AF2023LSK-269 |
First Posted: | August 30, 2023 Key Record Dates |
Last Update Posted: | August 30, 2023 |
Last Verified: | March 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Lung Neoplasms Pulmonary Embolism Embolism Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases |